Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials

Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…

AI Summary: Novo Nordisk’s much‑talked‑about GLP‑1 drug, famed for its weight‐loss benefits, has hit an unexpected wall in Alzheimer’s trials. In two separate reports – one on the standard injectable and another on a pill form – semaglutide showed no statistically significant impact on slowing brain decline. Who knew obesity meds couldn’t multitask?

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Novo Nordisk Seeks FDA Nod for Higher‐Dose Wegovy / 6 months

Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines / 2 months

Novo Nordisk slashes prices for Ozempic and Wegovy / 6 months

GLP‑1 drugs associated with lower addiction risk in large study / 2 months

Compounding Pharmacy Sues Lilly and Novo Nordisk / 4 months

Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 3 months

JP Morgan Healthcare Conference 2026: Pharma, AI, and Innovation Highlights / 4 months